Literature DB >> 19066849

Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies.

H Lode.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19066849     DOI： 10.1007/s00134-008-1366-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  16 in total

Review 1.  Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis.

Authors:  Djillali Annane; Eric Bellissant; Pierre Edouard Bollaert; Josef Briegel; Didier Keh; Yizhak Kupfer
Journal:  BMJ       Date:  2004-08-02

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 3.  Severe community-acquired pneumonia: approach to therapy.

Authors:  Lilibeth Pineda; Ali A El Solh
Journal:  Expert Opin Pharmacother       Date:  2007-04       Impact factor: 3.889

Review 4.  Adjunctive therapies for community-acquired pneumonia: a systematic review.

Authors:  Ilias I Siempos; Konstantinos Z Vardakas; Petros Kopterides; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2008-07-18       Impact factor: 5.790

5.  Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia.

Authors:  Stefano Aliberti; Asad Amir; Paula Peyrani; Mehdi Mirsaeidi; Marty Allen; Brian K Moffett; John Myers; Fidaa Shaib; Maria Cirino; Jose Bordon; Francesco Blasi; Julio A Ramirez
Journal:  Chest       Date:  2008-06-26       Impact factor: 9.410

6.  Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications.

Authors:  F Arancibia; S Ewig; J A Martinez; M Ruiz; T Bauer; M A Marcos; J Mensa; A Torres
Journal:  Am J Respir Crit Care Med       Date:  2000-07       Impact factor: 21.405

7.  Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

Authors:  R Menéndez; A Torres; R Zalacaín; J Aspa; J J Martín Villasclaras; L Borderías; J M Benítez Moya; J Ruiz-Manzano; F Rodríguez de Castro; J Blanquer; D Pérez; C Puzo; F Sánchez Gascón; J Gallardo; C Alvarez; L Molinos
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

Review 8.  The role of new therapies for severe community-acquired pneumonia.

Authors:  Marcos I Restrepo; Antonio Anzueto
Journal:  Curr Opin Infect Dis       Date:  2006-12       Impact factor: 4.915

Review 9.  Optimizing treatment outcomes in severe community-acquired pneumonia.

Authors:  Felipe Rodríguez de Castro; Antoni Torres
Journal:  Am J Respir Med       Date:  2003

10.  Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough.

Authors:  Alejandro Rodriguez; Thiago Lisboa; Stijn Blot; Ignacio Martin-Loeches; Jorge Solé-Violan; Diego De Mendoza; Jordi Rello
Journal:  Intensive Care Med       Date:  2008-12-10       Impact factor: 17.440
View more
  1 in total

Review 1.  Community-acquired pneumonia: identification and evaluation of nonresponders.

Authors:  João Gonçalves-Pereira; Catarina Conceição; Pedro Póvoa
Journal:  Ther Adv Infect Dis       Date:  2013-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.